Felix Gerhardt, Eva Fiessler, Karen M Olsson, Moritz Z Kayser, Gabor Kovacs, Henning Gall, H Ardeschir Ghofrani, Roza Badr Eslam, Irene M Lang, Nicola Benjamin, Ekkehard Grünig, Michael Halank, Tobias J Lange, Silvia Ulrich, Hanno Leuchte, Matthias Held, Hans Klose, Ralf Ewert, Heinrike Wilkens, Carmen Pizarro, Dirk Skowasch, Max Wissmüller, Martin Hellmich, Horst Olschewski, Marius M Hoeper, Stephan Rosenkranz
BACKGROUND: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes. METHODS: Patients diagnosed with PAH between January 1999 and December 2018 at 15 pulmonary hypertension centers were included and analyzed retrospectively...
April 12, 2024: Circulation